XML 38 R30.htm IDEA: XBRL DOCUMENT
v3.20.1

Subsequent events | 12 Months Ended
--- | ---
Dec. 31, 2019
Disclosure of non-adjusting events after reporting period [abstract] |
Subsequent events | 25. Subsequent events On January 2, 2020, the Company issued 27,580 Class B Common Shares as share-based compensation to certain Board of Directors for services performed as directors for the year-ended December 31, 2019. On January 9, 2020, the Company commenced trading on the NASDAQ under the symbol "HUGE". On February 4, 2020, the Company issued 225,371 Class B Common Shares to Solarvest as settlement under the Share Exchange Agreement to settle derivative liability of $2,646,269. The Company also concurrently announced the appointment of Dr. Edward J. Brennan, President of FSD Pharma's Biosciences Division, to the board of directors of Solarvest. On February 5, 2020 the Company executed Share Purchase and Sale Agreements with a consortium of buyers to sell the Company's investment in Cannara, consisting of 85,003,750 Class B shares, for gross proceeds of $7,743,492. Subsequent to December 31, 2019 the Company is considering the continuing use or sale of the Cobourg facility.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 10 -IssueDate 2019-01-01 -Paragraph 21 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2019-en-r&anchor=para_21&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration